Cool site pour acheter des pilules https://jacup.com/ Ne pas se perdre venir sur.

Publikation _kallinowski

Publikationen

Originalarbeiten

(1) D. Hüppe, E. Zehnter, S. Mauss, K. Böker, T. Lutz, S. Racky, W. Schmidt, J. Ul rich, I. Sbrijer, R. Heyne, A. Schober, C. John, KH. Hey, B. Bokemeyer, B. Kallinowski, B. Möl er, S. Pape, M.
Gutmann, U. Alshuth, C. Niederau. Epidemiology of chronic hepatitis C in Germany- an analysis of 10326 patients in hepatitis centres and outpatient units. Z Gastroenterol 2008; 46(1): 34-44 (2) D. Hüppe, E. Zehnter, S. Mauss, K. Böker, T. Lutz, S. Racky, W. Schmidt, J. Ul rich, I.Brijer, R. Heyne, A. Schober, C. John, K. Hey, B. Bokemeyer, B. Kallinowski, B. Möl er, S. Pape, M.
Tumenn, U. Alshuth, C. Niederau. Epidemiologie der chronischen Hepatitis C in Deutschland:
eine Analyse von 10326 Hepatitis C Infizierten aus Schwerpunktpraxen und -ambulanzen.
(3) U. Merle, F. Theilig, E. Fein, S. Gehrke, B. Kallinowski, HD. Riedel, S. Bachmann, W. Stremmel,
H. Kuaksiz. Localization of the iron-regulatory proteins hemojuvelin and transferrin receptor 2 to the basolateral membrane domain of hepatocytes. Histochem Cell Biol. 2007; 127(2): 221-226 (4) J. Wiegand, B. Buggisch, W. Boecher, S. Zeuzem, CM Gelbmann, T. Berg, W. Kauffmann, B.
Kallinowski, M. Cornberg, E. Jaeckel, H. Wedemeyer, MP Manns; German HEP-NET Acute HCV
Study Group. Early monotherapy with pegylated interferon-alpha-2b for acute hepatitis C
infection: the HEP-NET acute -HCV II study.
(5) T. Berg, M. von Wagner, W. Nasser, C. Sarrazin C, T. Heintges, T. Gerlach, P. Buggisch, T. Goeser, J. Rasenack, GR Pape, WE Schmidt, B. Kallinowski, H. Klinker, U. Spengler, P. Martus,
U. Alshuth, S. Zeuzem. Extended treatment duration for hepatitis C virus Tpye 1: comparing 48
versus 72 weeks of peginterferon-alfa-2a plus ribavirin.
Gastroenterology 2006; 130(4): 1086-1097 (6) B. Kasper, B. Kallinowski, T. Herrmann, T. Lehnert, G. Mechtersheimer, T. Geer, AD Ho, G.
Egerer. Treatment of Gastrointestinal stromal tumor with imatinib mesylate: a retrospective single-center experience in Heidelberg. (7) F. Nevens J.N. Zuckermann, A. Burroughs, M.C. Jung, J. Bayas, B. Kallinowski, E. Fraga Rivas,
C. Duvous, P. Neuhaus, F. Saliba, M. Buti, J. Zarski, F. Pons, C. Vanlemmens, V. Hamitaux, M. Stoffel. Immunogenicity and safety of an experimental adjuvanted hepatitis B candidate vaccine in liver transplant patients. (8) Nieters, B. Kallinowski, P. Brennan, M. Ott, M. Maynadie, Y Benavente, L. Foretova, PL. Cocco,
A. Staines, M. Vornanen, DE. Whitby, P. Boffetta, N. Becker, S. De Sanjose. Hepatitis C and risk of lymphoma:results of the European multicenter case-control study Epilymph Gastroenterology 2006; 131(6): 1879-1886 (9) B. Kallinowski. Indications and effect on survival of standard chemotherapy in advanced
Recent Results Cancer Res 2005;165: 245 -249 (10) C. Veltkamp, R. Sartor, T. Giese, F. Autschbach, I. Kaden, R. Veltkamp, D. Rost, B. Kallinowski,
W. Stremmel. Regulatory CD4+/CD25+ cel s reverse imbalances in the T cel pool of bone-marrow -transplanted TG(varepsilon) 26 mice leading to the prevention of colitis. (11) W. Jilg, C. Rink, B. Kallinowski. Immunprophylaxe der Hepatitis B
Z Gastroenterol 2004; 42: 698-702 (12) S. Sanjose, A. Nieters, J. Goedert, E Domingo-Domenech, A. de Sevil a, R. Bosch, P. Herrera, A. Domingo, J. Petit, X. Bosch, B. Kallinowski. Role of hepatitis C virus infection in malignant
lymphoma in Spain.
(13) H. Kulaksiz, S. Gehrke S, A. Janetzko, D. Rost, T. Bruckner, B. Kallinowski, W. Stremmel. Pro-
hepcidin: expression and cel -specific localisation in the liver and its regulation in hereditary hemochromatosis, chronic renal insufficiency and renal anemia. (14) S. Engler, C. Flechtenmacher, K. Wiedemann, R. Gugler, W. Stremmel, B. Kallinowski.
Interferon alfa 2a induction therapy in combination with ribavirin and amantadine for the treatment of naive patients with chronic HCV infection. (15) U. Siebert, G. Sroczynski, S. Rossol, J. Wasem, B. Kallinowski, U. Ravens-Sieberer, B. Kurth,
M. Manns, JG. McHutchison, JB. Wong, German Hepatitis C Model (GEHMO) Group, International Interventional Therapy (IHIT) Group. Cost effectiveness of peginterferon a-2b plus ribavirin versus interferon a-2b plus ribavirin for initial treatment of chronic hepatitis C. (16) S. Gehrke, W. Stremmel, I. Mathes, D. Riedel, K. Bents, B. Kallinowski. Hemochromatosis and
transferrin receptor gene polymorphisms in chronic hepatitis C: impact on iron status, liver injury and HCV genotype. (17) B. Kallinowski, W. Jilg, L. Buchholz, W. Stremmel, S. Engler. Immunogenicity of an accelerated
vaccination regime with a combined hepatitis A/B vaccine in patients with chronic hepatitis C. Z Gastroenterol 2003; 41 (10): 983-990 (18) L. Schwake, U. Mül er, L. Theilmann, W. Stremmel, B. Kallinowski. Clinical usefulness and
diagnostic value of percutaneous liver biopsy in patients with chronical y elevated liver enzymes of non-viral origin. Z Gastroenterol 2003; 41(4): 303-309 (19) S. Engler, P. Sauer, E. Klar, W. Stremmel, B. Kallinowski. Prophylaxis of hepatitis B recurrence
after liver transplantation with lamivudin and hepatitis B immunoglobulin. Transplant Proc 2002; 34 (6):2285-2287 (20) B. Kallinowski, S. Seipp, T. Dengler, E. Klar, L. Theilmann, W. Stremmel. Clinical impact of
hepatitis G virus infection in heart and liver transplant recipients. Transplant Proc 2002;34 (6): 2288-2291 (21) B. Kallinowski, O. Hergesel , M. Zeier. Clinical impact of hepatitis C virus infection in the renal
(22) O. Hergesel , B. Kallinowski, M. Wiesel, M. Zeier. Hepatitis C vor und nach Nierentranplantation.

Nieren- und Hochdruckkrankheiten, 2001; 12: 531-541 (23) S. Engler, P Sauer, C. Zapletal, M. Gol ing, E. Klar, C. Benz, W. Stremmel, B. Kallinowski.
Immunogenicity of two accelerated hepatitis B-vaccination protocols in liver transplant candidates. Europ J Gastroenterol Hepatol 2001; 13: 363-367 (24) B. Kallinowski, H. Liehr, B. Moel er, W. Stremmel, JG. Wechsler, M. Wiese T. Goeser.
Combination therapy with interferon a-2b and ribavirin for the treatment of relapse patients and nonresponders with chronic HCV infection. Z Gastroenterol 2001; 39: 199-206 (25) G. Teuber, HF Lohr, B. Kallinowski, T. Berg, R. Mul er, S.Zeuzem. Retrospective cohort study of
lamivudine therapy in patients with chronic hepatitis B. Dtsch Med Wochenschr 2001;126 (5): 97-102 (26) J. Pohl, W. Stremmel, B. Kallinowski. Pulmonale Sarkoidose: eine seltene Nebenwirkung einer
Interferon- a Therapie bei chronischer Hepatitis C Infektion. Z Gastroenterol 2000; 38: 951-955 (27) J. Pohl, T. Hess, W. Hofmann, W. Stremmel, B. Kallinowski. Spontaneous regression of
intrahepatic lesions mimicking metastatic disease. Z Gastroenterol 2000; 38: 803 - 806 (28) B. Kallinowski, A. Knöll, E. Lindner, R. Sänger, W. Stremmel, J. Vol mar, B. Zieger, W. Jilg. Can
monovalent hepatitis A and B vaccines be replaced by a combined heaptitis A/B vaccine during the primary seroconversion course? (29) B. Kallinowski, S. Scherer, A. Mehrabi, L. Theilmann, W. Stremmel. Clinical impact of HLA DRB1
genotypes in chronic hepatitis C virus (HCV) infection. Transplant Proceed 1999;31:3346-3349 (30) B. Kallinowski, M. Janicki, R. Seelig, S. Seipp, T. Dengler, P. Schnitzler, L. Theilmann, W.
Stremmel. Clinical impact of GBV-C infection after heart transplantation (HTX). J Heart Lung Transplant 1999 ;18: 190-193 (31) S. Seipp, M. Scheidel, W. Hofmann, U. Töx, L. Theilmann, T. Goeser, B. Kallinowski.
Hepatotropism of GB virus (GBV-C): GBV-C replication in human hepatocytes and cel s of human hepatoma cel lines. (32) S. Gehrke, I. Henrich, J. Mytilineos, H. Riedel, T. Herrmann, B. Kallinowski, W. Stremmel.
Verdauungskrankheiten 1998; (5): 223 -229 (33) S. Seipp, T. Goeser, L. Theilmann, B. Kallinowski. Establishment of a highly specific detection
system for GB virus C (GBV-C) minus strand RNA. Virus Research 1998; 56: 183 – 189 (34) B. Kallinowski, C. Benz, L. Buchholz, W. Stremmel. Accelerated schedule of hepatitis B
vaccination in liver transplant candidates. Transplant Proc. 1998; 30: 797 -799 (35) B. Kallinowski, R. Ahmadi, S. Seipp, H.M. Mül er, T. Goeser, J. Bommer, W. Stremmel. Clinical
impact of GB-C virus in hemodialysis patients. Nephrol Dial Transplant 1998;13: 93 -98 (36) B. Kallinowski, C. Buhrmann, S. Seipp, T. Goeser, W. Stremmel, G. Otto, L.Theilmann.
Incidence, prevalence and clinical outcome of GBV-C infection in liver transplant patients. Liver Transplant Surg 1998; 4: 28 -33 (37) B. Kallinowski, K. Haseroth, G. Marinos, W. Stremmel, L. Theilmann, M.V. Singer, S. Rossol.
Induction of TNF-a and TNF receptor type p55 and p75 in patients with chronic hepatitis C virus (HCV) infection. Clin Exp Immunol 1998;111: 269 – 277 (38) M. Möhler, F. Gutzler, B. Kallinowski, T. Goeser, W. Stremmel. Primary hepatic high-grade Non-
Hodgkins's Lymphoma and chronic hepatitis C infection. Dig Dis Sci, 1997, 42: 2241 – 2245 (39) B. Kallinowski, W. Stremmel. Prävention viraler Hepatitiden: neue und bekannte Impfstoffe.
Klinikarzt 1997;6 (26): 150 - 155 (40) B. Kallinowski, S. Seipp, S. Fatehi, U. Sommerfeld, K. Andrassy, W. Stremmel, L. Theilmann.
Significance of hepatitis, B, hepatitis C and GBV-C in ANCA-positive hemodialysis patients. (41) B. Kallinowski, H.L. Bock, R. Clemens, L. Theilmann. Immunogenicity and reactogenicity of a
combined hepatitis A/B candidate vaccine: first results. (42) L. Theilmann, C. Solbach, U. Töx, B. Kallinowski, T. Goeser. Bedeutung der Hepatitis -C- Virus-
Münch Med Wschr. 1995; (137) 44: 699 -701 (43) B. Kallinowski, H.L. Bock, R. Clemens, L. Theilmann. Immunogenität und Verträglichkeit eines
kombinierten Hepatitis A/B Impfstoffes: erste Ergebnisse mit einer Kandidatvakzine. Dtsch Med Wschr 1995; 120: 1426 – 1429 (44) H.J. Arnold, B. Heilig, B. Kallinowski, G. Otto, B. Kommerel , L. Theilmann. Soluble tumor
necrosis factor receptors in patients with recurrent hepatitis C virus infection after liver transplantation. J Clin Invest 1994; 72 (194): 470 (45) B. Kallinowski, W. Nöldge, A. Stiehl. Crohn's disease with Behcet's syndrome like appearence: a
Z Gastroenterol 1994;32: 642 – 644 (46) H. M. Mül er, B. Kallinowski, C. Solbach, L.Theilmann, T. Goeser, E. Pfaff. B-lymphocytes are
predominantly involved in viral propagation of hepatitis C virus (HCV). Arch Virol (Suppl). 1994; 9: 307 – 316 (47) B. Kallinowski, H. M. Mül er, Ch. Solbach, T. Goeser, D. Kabelitz, L. Theilmann. Hepatitis C virus
RNA in different blood lymphocyte subsets. Eur J Gastroenterol Hepatol 1994, 6: 249 – 252 (48) H.M. Mül er, E. Pfaff, T. Goeser, B. Kallinowski, C. Solbach, L. Theilmann. Peripheral blood
leukocytes serve as a possible extrahepatic site for viral replication. (49) B. Kallinowski, L. Theilmann. Die Hepatitis C: eine Übersicht über Klinik, Diagnostik, Therapie
Krankenpflegejournal 1993;31: 38 – 40 (50) K. Gmelin, F. Kurzen, B. Kallinowski, T. Goeser, J. Arnold, B. Kommerel , L. Theilmann. Fol ow-
up of patients with hepatitis non-A, non-B: incidence and persistence of anti-HCV depend on route of transmission. Arch Virol 1992 (Suppl) 4: 222 – 2224 (51) B. Kallinowski, L. Theilmann, K. Gmelin, B. Kommerel , F. Hofmann, N. Scheiermann,
B.Wohland, H. Stickl, H. Maiwald, K. Moriabadi, H. L. Bock, R. Clemens. Immunogenität, Verträglichkeit und Konsistenz eines inaktivierten Hepatitis-A-Impfstoffes: eine randomisierte, kontrol ierte Multicenterstudie mit drei konsekutiven Impfchargen. (52) L. Theilmann, B. Kallinowski, K. Gmelin, F. Hofmann, N. Scheiermann, B. Wohland, H. Stickl, H.
Maiwald, K. Moriabadi, H.L. Bock, R. Clemens, A. Safary. F. E. Andre. Reactogenicity, and immunogenicity of three different lots of a hepatitis A vaccine. Vaccine 1992;10 (Suppl. 1): 132 – 134 (53) B. Kallinowski, K. Gmelin, B. Kommerel , H.L. Bock, R. Clemens, N. Scheiermann, B. Wohland,
F. Hofmann, L. Theilmann. Immunogenicity, reactogenicity and consistency of a new, inactivated hepatitis A vaccine - a randomized multicentre study with three consecutive vaccine lots. Vaccine 1992; 10 (8) : 500 – 501 (54) B. Kallinowski, B. Aulmann, B. Kommerel , L. Theilmann. Hepatitis A: ein up-date.
Klinikarzt 1992; 21 (8) : 381 – 389 (55) L. Theilmann, K. Gmelin, B. Kallinowski, B. Kommerel , J. Koderisch, K. Andrassy. Prevalence of
antibodies to hepatitis C virus in sera from patients with systemic necrotizing vasculitis. (56) B. Kallinowski, W. J. Hofmann , K. Gmelin , U. Töx , B. Kommerell , L. Theilmann. Therapie der
chronischen Hepatitis C und Non-A Non-B mit a-Interferon. (57) B. Kallinowski, L. Theilmann, K. Gmelin, K. Andrassy, D. Deppermann, B. Weinel, B.
Kommerel .Prevalence of antibodies to hepatitis C virus in hemodialysis patients. (58) B. Kallinowski, L. Theilmann, K. Gmelin, M. Rambausek, M. Möhring, B. Kommerel . Incidence
and prevalence of antibodies to hepatitis C virus in kidney transplant patients. (59) B. Kallinowski, L. Theilmann, R. Zimmerrmann , E. Gams , B. Kommerel , A. Stiehl. Effective
treatment of cyclosporine-induced cholestasis in heart-transplanted patients treated with ursodeoxycholic acid. Transplantation 1991;51 (5) : 1128 – 1129

Source: http://gastroenterologie-schwetzingen.de/index_htm_files/Publikationen.pdf

Energrease lc 2

Energrease LC 2 High Performance Lithium Complex Grease Description Energrease LC 2 is a multi-purpose, high-performance grease, based on mineral oil and a lithium-complex soap and containing a red dye to differentiate from conventional soap type lithium greases. It is formulated to provide excellent high-temperature lubrication performance. Energrease LC 2 has EP load-carrying properties and

Pdf template (pages) copy

Antibiotics - Some Facts When bacteria invade the body, a bacterial infection is present. Often, the bacteria are removed by our own immune system before there are any obvious signs of disease. But if bacteria multiply faster than our immune system can destroy them, an infectious disease develops. An infectious disease is treated by drugs that harm the bacteria, either by killing them or by

Copyright © 2010-2014 Predicting Disease Pdf